Revolution Medicines (RVMD)
(Delayed Data from NSDQ)
$43.64 USD
+0.38 (0.88%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $43.63 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
RVMD 43.64 +0.38(0.88%)
Will RVMD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RVMD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RVMD
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?
RVMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates
Wall Street Analysts See a 27.5% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High?
Other News for RVMD
Wall Street Analysts Are Bullish on Top Healthcare Picks
Revolution Medicines: A Strong Buy on Robust Financials and Promising Clinical Pipeline
Revolution Medicines, Inc. 2024 Q2 - Results - Earnings Call Presentation
Revolution Medicines, Inc. (RVMD) Q2 2024 Earnings Call Transcript
Revolution Medicines Maintains Buy Rating Amid Promising Clinical Progress and Strong Financial Standing